European journal of pharmacology · 2026
Mogrol protects against warm hepatic ischemia-reperfusion injury by preserving mitochondrial function through PI3K/AKT/GSK3β signaling.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ruan Wenzheng, Zhu Ying, Zhao An, Fang Haoran, Yu Qiwen, Cao Shengli
Аннотация
BACKGROUND: Warm hepatic ischemia-reperfusion injury (HIRI) is a common complication of liver surgery that significantly impairs clinical outcomes, and effective therapeutic strategies remain limited. Mogrol is a bioactive component derived from Siraitia grosvenorii that exhibits potent anti-inflammatory and antioxidant properties; however, its role in warm HIRI and the underlying mechanisms remain largely unexplored.
METHODS: The effects of Mogrol were investigated using an in vivo warm hepatic I/R model with mice and an in vitro hypoxia/reoxygenation model with AML12 cells. Mogrol was administered with or without the PI3K inhibitor LY294002. Liver function, histopathology, oxidative stress, inflammatory responses, and mitochondrial function were assessed using biochemical assays, fluorescence staining, transmission electron microscopy (TEM), and adenosine triphosphate (ATP) measurements. Transcriptomic analysis, molecular docking, cellular thermal shift assay (CETSA), and western blotting were performed to explore the underlying mechanisms.
RESULTS: Mogrol pretreatment significantly reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, alleviated hepatic necrosis, suppressed oxidative stress and inflammatory responses, restored mitochondrial ultrastructure, stabilized mitochondrial membrane potential (MMP), inhibited mitochondrial permeability transition pore (mPTP) opening, enhanced ATP production, and attenuated mitochondria-mediated apoptosis in both in vivo and in vitro models. These protective effects were partially reversed by LY294002.
CONCLUSION: Mogrol mitigates warm HIRI, at least in part, by activating the PI3K/AKT/GSK3β signaling pathway, thus highlighting its potential as a naturally derived candidate for liver protection.
METHODS: The effects of Mogrol were investigated using an in vivo warm hepatic I/R model with mice and an in vitro hypoxia/reoxygenation model with AML12 cells. Mogrol was administered with or without the PI3K inhibitor LY294002. Liver function, histopathology, oxidative stress, inflammatory responses, and mitochondrial function were assessed using biochemical assays, fluorescence staining, transmission electron microscopy (TEM), and adenosine triphosphate (ATP) measurements. Transcriptomic analysis, molecular docking, cellular thermal shift assay (CETSA), and western blotting were performed to explore the underlying mechanisms.
RESULTS: Mogrol pretreatment significantly reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, alleviated hepatic necrosis, suppressed oxidative stress and inflammatory responses, restored mitochondrial ultrastructure, stabilized mitochondrial membrane potential (MMP), inhibited mitochondrial permeability transition pore (mPTP) opening, enhanced ATP production, and attenuated mitochondria-mediated apoptosis in both in vivo and in vitro models. These protective effects were partially reversed by LY294002.
CONCLUSION: Mogrol mitigates warm HIRI, at least in part, by activating the PI3K/AKT/GSK3β signaling pathway, thus highlighting its potential as a naturally derived candidate for liver protection.